Journal
JOURNAL OF MOLECULAR NEUROSCIENCE
Volume 41, Issue 1, Pages 129-137Publisher
HUMANA PRESS INC
DOI: 10.1007/s12031-009-9302-8
Keywords
Multiple sclerosis (MS); Mesenchymal stem cells (MSCs); Experimental autoimmune encephalomyelitis (EAE)
Categories
Funding
- Norma and Alan Aufzein Chair for Parkinson's Disease Research
Ask authors/readers for more resources
Stem cell-based therapy holds great potential for future treatment of multiple sclerosis (MS). Bone marrow mesenchymal stem cells (MSCs) were previously reported to ameliorate symptoms in mouse MS models (experimental autoimmune encephalomyelitis, EAE). In this study, we induced MSCs to differentiate in vitro into neurotrophic factor-producing cells (NTFCs). Our main goal was to examine the clinical use of NTFCs on EAE symptoms. The NTFCs and MSCs were transplanted intracerebroventricularly (ICV) to EAE mice. We found that NTFCs transplantations resulted in a delay of symptom onset and increased animal survival. Transplantation of MSCs also exerted a positive effect but to a lesser extent. In vitro analysis demonstrated the NTFCs' capacity to suppress mice immune cells and protect neuronal cells from oxidative insult. Our results indicate that NTFCs-transplanted ICV delay disease symptoms of EAE mice, possibly via neuroprotection and immunomodulation, and may serve as a possible treatment to MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available